#AbbVie Inc (ABBV) - Prohost Biotech

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

AbbVie and RemeGen Announce Licensing Agreement Today, January 12, 2026, - AbbVie ( ABBV ) and RemeGen announced an exclusive licensing agreement for the development, manufacturing and commercializat...

P

Prohost Biotech

Jan 12, 2026

About Making Sense, Date of Moderna's Q2nd Financial Results and AbbVie’s Agreement

The root-cause of the stock market’s volatility and inflation does not make sense as we are reading and hearing it. At the end of this week, we will post an article about this important subject, which...

P

Prohost Biotech

Jul 16, 2025

Important Biotechnology Companies' News, Plus News from the American Association for Cancer Research and More

Important News from AbbVie AbbVie ( ABBV ) submitted a biological license application ( BLA ) to the United States’ FDA for its sensational product trenibotulinumtoxinE (TrenibotE), which reduces frow...

P

Prohost Biotech

Apr 29, 2025

1m

23

News & Comments

U.S. FDA Approves AbbVie's VYALEV™ for Adults Living with Advanced Parkinson's Disease

AbbVie FDA Approval for VYALEV for Parkinson's Disease AbbVie (ABBV) announced that the U.S. FDA approved VYALEV™ (foscarbidopa and levodopa) as the first and only subcutaneous 24-hour infusion of...

P

Prohost Biotech

Oct 17, 2024

AbbVie Inc's Two Different, Yet, Positive Impacting News

AbbiVie Inc's Acquisition and Approval 1. AbbVie's Acquisition AbbVie Inc. ( ABBV ) and Landos Biopharma, Inc . ( LABP ) announced a definitive agreement under which AbbVie will acquire Landos Biop...

P

Prohost Biotech

Mar 26, 2024

AbbVie Inc to Acquire ImmunoGen

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. ( ABBV ) and ImmunoGen ( IMGN ) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer th...

P

Prohost Biotech

Nov 30, 2023

1m

18

News & Comments

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.

AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc (ABBV) announced detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 m...

P

Prohost Biotech

Nov 17, 2023

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn's Disease

Offsetting the Biotech Firms' Good News There is no doubt that good news is filling the media about outperformances of both development-stage small biotech firms and revenues-generating firms. This go...

P

Prohost Biotech

Jul 29, 2022

An Important Milestone for Regenxbio Treatment of Wet AMD

Regenxbio Good News for wet AMD On January 10, 2022, Regenxbio Inc. ( RGNX ) announced the initiation of ASCENT, the second of two Phase 3 pivotal trials to evaluate the efficacy and safety of subre...

P

Prohost Biotech

Feb 8, 2022

Regenxbio and AbbVie Inc Agreement. See Also: Gilead Sciences and Everest Medicines News

Regenxbio and AbbVie Inc Agreement Regenxbio ( RGNX ) announced the successful closure of the collaboration and license agreement with AbbVie Inc ( ABBV ) for the development and commercialization of...

P

Prohost Biotech

Nov 12, 2021

Regenxbio and AbbVie: A Good Reason for RGNX to Soar Today

Regenxbio and AbbVie in the NEWS Regenxbio ( RGNX ) stock soared today. The Company, along with AbbVie ( ABBV ), announced a partnership to develop and commercialize RGX-314, a potential one-time gene...

P

Prohost Biotech

Sep 13, 2021

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX ( CTMX ) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® techno...

P

Prohost Biotech

Apr 30, 2020

Enanta Product EPD-305 Has Promising Results for the Treatment NASH

Enanta Positive Results of EPD-305 for NASH Enanta ( ENTA ) has positive results from the ARGON-1 Phase 2 study evaluating the safety, tolerability pharmacokinetics and efficacy of its product EPD-305...

P

Prohost Biotech

Sep 28, 2019

1m

14

News & Comments

Argenx's product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

Phase 2 clinical trial data of argenx’s (ARGX) product Efgartigimod (ARGX-113) in adult patients with primary immune thrombocytopenia (ITP) showed a favorable safety and tolerability profile. The res...

P

Prohost Biotech

Sep 17, 2018

The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target

AbbVie (NYSE: ABBV) , in cooperation with Neurocrine Biosciences (NBIX) , announced that the United States FDA approved Orilissa ™ (elagolix) under priority review for women with moderate to severe en...

P

Prohost Biotech

Jul 25, 2018

Stories about research, clinical trials results and an FDA ruling

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its...

P

Prohost Biotech

Jul 9, 2018

Revisiting Biotech Companies We Highlighted

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same reasons other industries’ stock prices swing all day long. The fluctuations are the out...

P

Prohost Biotech

May 25, 2018

Another Week of Outperformance

The Week in Review #16 More Exciting Rallies in Prohost Picks - The past week and for several week fascinating outperformances have been seen for many of the Prohost Portfolio stocks. We continue to a...

P

Prohost Biotech

Jan 16, 2018

Tracing Large Pharmaceutical Companies' Choices

The Week in Review #8 Potential biotech winners inspired through COLLABORATION - When successful top-tier drug developing firms such as Amgen (AMGN) or Merck (MRK) sign strategic collaborating agreem...

P

Prohost Biotech

Oct 16, 2017

New Breakthrough Immuno-Oncology Products

The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthr...

P

Prohost Biotech

Oct 9, 2017

1m

20